These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24241057)

  • 21. In-treatment stroke volume predicts cardiovascular risk in hypertension.
    Lønnebakken MT; Gerdts E; Boman K; Wachtell K; Dahlöf B; Devereux RB
    J Hypertens; 2011 Aug; 29(8):1508-14. PubMed ID: 21720264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
    Salles GF; Cardoso CR; Muxfeldt ES
    Arch Intern Med; 2008 Nov; 168(21):2340-6. PubMed ID: 19029499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study.
    Mancia G; Parati G; Bilo G; Choi J; Kilama MO; Ruilope LM;
    J Hypertens; 2011 Mar; 29(3):600-9. PubMed ID: 21252701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Importance of Resistant Hypertension in Patients With Type 2 Diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Bacan G; Ataíde DS; Gorgonio LKC; Salles GF
    Diabetes Care; 2020 Jan; 43(1):219-227. PubMed ID: 31619394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex-specific cardiovascular morbidity and mortality in a cohort treated for hypertension.
    Li C; Engström G; Hedblad B; Janzon L
    J Hypertens; 2006 Aug; 24(8):1523-9. PubMed ID: 16877954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management.
    de Souza F; Muxfeldt ES; Salles GF
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):735-45. PubMed ID: 22894630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study.
    Salles GF; Cardoso CR; Muxfeldt ES
    J Hypertens; 2009 May; 27(5):1094-101. PubMed ID: 19390353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension.
    Fagard RH; Thijs L; Staessen JA; Clement DL; De Buyzere ML; De Bacquer DA
    J Hum Hypertens; 2009 Oct; 23(10):645-53. PubMed ID: 19225527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with resistant hypertension in a large cohort of hypertensive patients: the Pol-Fokus study.
    Prejbisz A; Klocek M; Gąsowski J; Topór-Mądry R; Leśniak W; Kabat M; Czarnecka D; Kawecka-Jaszcz K; Narkiewicz K; Januszewicz A
    Pol Arch Med Wewn; 2015; 125(4):249-59. PubMed ID: 25764004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.
    de la Sierra A; Banegas JR; Oliveras A; Gorostidi M; Segura J; de la Cruz JJ; Armario P; Ruilope LM
    J Hypertens; 2012 Jun; 30(6):1211-6. PubMed ID: 22525201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic characteristics of resistant hypertension in the Brazilian population.
    Faria AP; Sabbatini AR; Coca A; Moreno H
    Arq Bras Cardiol; 2013 Jun; 100(6):579-82. PubMed ID: 23657267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension.
    Clement DL; De Buyzere ML; De Bacquer DA; de Leeuw PW; Duprez DA; Fagard RH; Gheeraert PJ; Missault LH; Braun JJ; Six RO; Van Der Niepen P; O'Brien E;
    N Engl J Med; 2003 Jun; 348(24):2407-15. PubMed ID: 12802026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes.
    Ayala DE; Moyá A; Crespo JJ; Castiñeira C; Domínguez-Sardiña M; Gomara S; Sineiro E; Mojón A; Fontao MJ; Hermida RC;
    Chronobiol Int; 2013 Mar; 30(1-2):99-115. PubMed ID: 23098178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.
    Ayala DE; Hermida RC; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):340-52. PubMed ID: 23077973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.